Suppr超能文献

氯胺酮对危重症患者预后的影响:一项对随机对照试验的系统评价、荟萃分析及试验序贯分析

The impact of ketamine on outcomes in critically ill patients: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials.

作者信息

Abdildin Yerkin, Tapinova Karina, Nemerenova Assel, Viderman Dmitriy

机构信息

Department of Mechanical and Aerospace Engineering, School of Engineering and Digital Sciences, Nazarbayev University, Astana, Kazakhstan.

Department of Emergency Medicine, Medical University of Vienna, Vienna, Austria.

出版信息

Acute Crit Care. 2024 Feb;39(1):34-46. doi: 10.4266/acc.2023.00829. Epub 2024 Feb 28.

Abstract

BACKGROUND

This meta-analysis aims to evaluate the effects of ketamine in critically ill intensive care unit (ICU) patients.

METHODS

We searched for randomized controlled trials (RCTs) in PubMed, Scopus, and the Cochrane Library; the search was performed initially in January but was repeated in December of 2023. We focused on ICU patients of any age. We included studies that compared ketamine with other traditional agents used in the ICU. We synthesized evidence using RevMan v5.4 and presented the results as forest plots. We also used trial sequential analysis (TSA) software v. 0.9.5.10 Beta and presented results as TSA plots. For synthesizing results, we used a random-effects model and reported differences in outcomes of two groups in terms of mean difference (MD), standardized MD, and risk ratio with 95% confidence interval. We assessed the risk of bias using the Cochrane RoB tool for RCTs. Our outcomes were mortality, pain, opioid and midazolam requirements, delirium rates, and ICU length of stay.

RESULTS

Twelve RCTs involving 805 ICU patients (ketamine group, n=398; control group, n=407) were included in the meta-analysis. The ketamine group was not superior to the control group in terms of mortality (in five studies with 318 patients), pain (two studies with 129 patients), mean and cumulative opioid consumption (six studies with 494 patients), midazolam consumption (six studies with 304 patients), and ICU length of stay (three studies with 270 patients). However, the model favored the ketamine group over the control group in delirium rate (four studies with 358 patients). This result is significant in terms of conventional boundaries (alpha=5%) but is not robust in sequential analysis. The applicability of the findings is limited by the small number of patients pooled for each outcome.

CONCLUSIONS

Our meta-analysis did not demonstrate differences between ketamine and control groups regarding any outcome except delirium rate, where the model favored the ketamine group over the control group. However, this result is not robust as sensitivity analysis and trial sequential analysis suggest that more RCTs should be conducted in the future.

摘要

背景

本荟萃分析旨在评估氯胺酮对重症监护病房(ICU)重症患者的影响。

方法

我们在PubMed、Scopus和Cochrane图书馆中检索随机对照试验(RCT);最初在1月进行检索,但在2023年12月重复检索。我们关注任何年龄的ICU患者。我们纳入了比较氯胺酮与ICU中使用的其他传统药物的研究。我们使用RevMan v5.4合成证据,并以森林图形式呈现结果。我们还使用了试验序贯分析(TSA)软件v. 0.9.5.10 Beta,并以TSA图形式呈现结果。为了合成结果,我们使用随机效应模型,并报告两组在平均差(MD)、标准化MD和风险比方面的结果差异以及95%置信区间。我们使用Cochrane随机对照试验偏倚风险工具评估偏倚风险。我们的结局指标包括死亡率、疼痛、阿片类药物和咪达唑仑的使用量、谵妄发生率以及ICU住院时间。

结果

荟萃分析纳入了12项RCT,涉及805例ICU患者(氯胺酮组,n = 398;对照组,n = 407)。在死亡率(5项研究,318例患者)、疼痛(2项研究,129例患者)、平均和累积阿片类药物消耗量(6项研究,494例患者)、咪达唑仑消耗量(6项研究,304例患者)以及ICU住院时间(3项研究,270例患者)方面,氯胺酮组并不优于对照组。然而,在谵妄发生率方面(4项研究,358例患者),模型显示氯胺酮组优于对照组。就传统界值(α = 5%)而言,这一结果具有统计学意义,但在序贯分析中并不稳健。每个结局指标纳入的患者数量较少限制了研究结果的适用性。

结论

我们的荟萃分析表明,除了谵妄发生率(模型显示氯胺酮组优于对照组)外,氯胺酮组和对照组在任何结局指标上均无差异。然而,敏感性分析和试验序贯分析表明,未来应开展更多的随机对照试验,因此这一结果并不稳健。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验